HalioDx SAS, the immuno-oncology diagnostic company, today announced that Immunoscore® has been included in the 2020 European Society of Medical Oncology (ESMO) Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up for Localised Colon Cancer.
In these guidelines, Immunoscore® is considered for its ability to refine the prognosis of early colon cancer patients, in conjunction with the TNM* scoring and thus to adjust the chemotherapy decision-making process in stage II and in low-risk stage III patients.
These guidelines complement the WHO (IARC) introduction of immune response as an important element of risk assessment for colorectal cancer, in addition to traditional histologic parameters.
“With increasing accuracy in patient’s risk of recurrence, precision medicine substantially improves therapeutic strategies”,said Pr. Josep Tabernero, from Barcelona, Director of Vall d’Hebron Institute of Oncology (VHIO) and co-author of guidelines. “Immunoscore® can be helpful to adjust the chemotherapy decision, notably when we have choices to make between quality of life and risk of relapse.“
“We are pleased that ESMO recognizes the extensive clinical validation of Immunoscore® in localised Colon cancer and consider it a significant milestone in our strategy to facilitate access to Immunoscore® testing through patient assistance programs and reimbursement initiatives,” said Vincent Fert, CEO of HalioDx.
The ESMO Guidelines are updated regularly to ensure the inclusion of the latest and most effective practices.
* Tumour, Node, Metastasis